Meeting
2016 Genitourinary Cancers Symposium
Genomic and imaging biomarkers associated with cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).
Authors
Ulka N. Vaishampayan
Karmanos Cancer Institute, Wayne State University, Detroit, MI
Ulka N. Vaishampayan , Izabela Podgorski , Lance K. Heilbrun , Daryn W. Smith , Jawana Lawhorn-Crews , Kimberlee Dobson , Joseph A. Fontana , Elisabeth I. Heath , Anthony Frank Shields
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 212)
DOI
10.1200/jco.2016.34.2_suppl.212
Abstract #
212
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2021 Genitourinary Cancers Symposium
Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.
First Author: Morgan Goujon
Poster
2021 Genitourinary Cancers Symposium
PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Jodi Lyn Layton
Poster
2021 Genitourinary Cancers Symposium
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.
First Author: Adam Kessel